These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib. Kim DS; Lee S; Choi CW Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427 [No Abstract] [Full Text] [Related]
13. Imatinib for the treatment of hypereosinophilic syndromes. Helbig G Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368 [TBL] [Abstract][Full Text] [Related]
14. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602 [TBL] [Abstract][Full Text] [Related]
15. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Pitini V; Sturniolo G; Cavallari V; Arrigo C Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645 [No Abstract] [Full Text] [Related]
16. Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα. Tsuda K; Tanimoto T; Hayakawa K; Komatsu T BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26759442 [No Abstract] [Full Text] [Related]
17. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808 [TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504 [TBL] [Abstract][Full Text] [Related]
19. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374 [TBL] [Abstract][Full Text] [Related]
20. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]